|1.||Denmeade, Samuel R: 2 articles (09/2003 - 02/2002)|
|2.||Ratain, Mark J: 1 article (11/2004)|
|3.||Mani, Sridhar: 1 article (11/2004)|
|4.||Mauer, Ann M: 1 article (11/2004)|
|5.||Vogelzang, Nicholas J: 1 article (11/2004)|
|6.||Undevia, Samir D: 1 article (11/2004)|
|7.||Janisch, Linda: 1 article (11/2004)|
|8.||Rosen, Mark: 1 article (09/2003)|
|9.||Ball, Douglas W: 1 article (09/2003)|
|10.||Jones-Bolin, Susan: 1 article (09/2003)|
08/07/1997 - "CEP-751 exhibited anti-tumor efficacy against tumors derived from NIH3T3 cells transfected with trkA. "
01/01/2001 - "CEP-751 had little effect on the growth of SY5Y tumors, but did slow the growth rate of the C8 and G12 tumors. "
08/01/1998 - "CEP-751 is selective for cancerous versus normal prostate cells and affects the growth of only a limited number of nonprostate tumors. "
08/07/1997 - "Our data indicate that CEP-751 is a potent trk inhibitor which possesses anti-tumor activity."
05/15/1999 - "However, the combination of castration and concomitant CEP-751 produced the most dramatic results: sigificantly greater tumor regression than either therapy alone, with no signs of regrowth. "
|2.||Prostatic Neoplasms (Prostate Cancer)
10/01/2000 - "The consequence of CEP-751 inhibition of trk signaling for in vitro clonogenic survival of a series of human prostatic cancer lines was also tested. "
05/15/1999 - "In the slow-growing, androgen-sensitive Dunning H prostate cancers, which express trk receptors, CEP-751 induced transient regressions independent of effects on cell cycle. "
05/15/1999 - "Because androgen ablation is the most commonly used treatment for prostate cancer, we examined whether the combination treatment of CEP-751 with castration would lead to better antitumor efficacy than either treatment alone. "
02/15/2002 - "The indocarbazole compounds, CEP-701 and CEP-751, are potent inhibitor of this Trk receptor survival signaling and thus selectively induces apoptosis of prostate cancer cells in various in vitro and in vivo models. "
05/15/1999 - "In summary, these data demonstrate that CEP-751 or CEP-701, when combined with surgically or chemically induced androgen ablation, offer better antitumor efficacy than either monotherapy and suggest that each therapy produces prostate cancer cell death through complementary mechanisms."
01/01/2001 - "Effect of CEP-751 (KT-6587) on neuroblastoma xenografts expressing TrkB."
01/01/2001 - "These data suggest that the effect of CEP-751 is due, at least in part, to its inhibition of TrkB kinase, and that CEP-751 may become a useful therapeutic tool for the treatment of aggressive neuroblastomas, which often express TrkB."
11/01/1999 - "Antitumor activity of CEP-751 (KT-6587) on human neuroblastoma and medulloblastoma xenografts."
01/01/2001 - "The compound CEP-751 (KT-6587), a potent and selective inhibitor of the Trk family of tyrosine kinases, has been shown to inhibit the growth of human neuroblastoma (NB) xenografts in nude mice . "
|4.||Thyroid Neoplasms (Thyroid Cancer)
|2.||tyrosine receptor (receptor, tyrosine)
|3.||DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)
|4.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|8.||Protein Kinase Inhibitors
|1.||Heterologous Transplantation (Xenotransplantation)